France’s controversial 2025 social security financing bill (PLFSS), which contains €1bn ($1.05bn) worth of medicine price cuts and changes to the clawbacks paid by pharma companies, has finally passed through the French parliament, offering more certainty to firms operating in Europe’s second biggest pharmaceutical market.
France Finally Passes Price Cutting Finance Bill – With Some Amendments
Some changes to the contentious social security financing bill have been made, but industry and the government remain at odds over a €1.2bn drugs overspend.
